Concepedia
Statistics
Publications
12
Citations
2.4K
H-Index
Active since
1998
Affiliations
Novartis (Switzerland)(Current)
Novartis (United Kingdom)
Johannes Gutenberg University Mainz
University Medical Center of the Johannes Gutenberg University Mainz
Fudan University Shanghai Cancer Center
J. Thirlwell is an author at Novartis (Switzerland) specializing in pharmacotherapy, pharmacology, and omalizumab therapy.
Publications per year
1998–2018
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
M. Solèr, Jonathan Matz, Robert G. Townley et al. · European Respiratory Journal · 2001 · 826 citations · Full text
Life Sciences, Pharmacology, Pharmacotherapy +17
Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma
Stephen T. Holgate, Jean‐Louis Hébert, Jan Lötvall et al. · Clinical & Experimental Allergy · 2004 · 520 citations
Pharmacy, Pharmacology, Pharmacotherapy +16
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen–induced seasonal allergic rhinitis
E Ädelroth, S. Rak, Tari Haahtela et al. · Journal of Allergy and Clinical Immunology · 2000 · 318 citations · Full text
Life Sciences, Immunology, Allergy +15
Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma
Roland Buhl, M. Solèr, Jonathan Matz et al. · European Respiratory Journal · 2002 · 180 citations · Full text
Pharmacy, Pharmacology, Pharmacotherapy +15
Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
Claus Vogelmeier, Péter Kardos, Sergio Harari et al. · Respiratory Medicine · 2008 · 171 citations · Full text
Medicine, Clinical Sciences, Pharmacotherapy +9
1–5 of 12